Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT03422822 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3166

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: Abrocitinib 100 mg
DRUG: Abrocitinib 200 mg
DRUG: Placebo
DRUG: Abrocitinib 100 mg
DRUG: Abrocitinib 100 mg
DRUG: Abrocitinib 200 mg

Sponsor

Pfizer